PEB Shares Pacific Edge Limited
ASX · ASXLast in our picks 2026-09-28 — not in the current list; analysis below is from that screen
Diagnostics turnaround play with possible rerating if reimbursement and commercial traction improve.
Signal breakdown
- ▸Turnaround optionality, but fundamentals still fragile.
- ▸Above 50-day MA (+1.83%)
- ▸Above 200-day MA — long-term uptrend
Is PEB a buy right now?
Trend: PEB is trading below the 50-day average (-5.00%), RSI 56 — neutral momentum, with a 3-month return of -13.64%.
Valuation & quality: Pacific Edge Limited trades on price-to-book 23.42; fundamentals show net margin -275.0%, return on equity -194.7%, revenue growth -45.8% year on year.
Our screen: BUY (score 2) — Diagnostics turnaround play with possible rerating if reimbursement and commercial traction improve.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -22.20% | +7.10% | +46.70% | +13.60% | -8.00% | -8.70% | +4.80% | -13.60% |
Fundamentals
Technical signals
About Pacific Edge Limited
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research.
Sector: Healthcare · Industry: Diagnostics & Research · New Zealand · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.